Enhanced striatal dopamine neurotransmission3 and prefrontal cortex dysfunction4 are consist findings in schizophrenia that might correlated to functional impairments and cognitive deficits in schizophrenia5, and the striatal dopamine D2 receptor is the therapeutic target of most antipsychotic drugs5. Here, DRD2 is linked to schizophrenia.